Lung Cancer

Lung Cancer Tracey L. Evans, Thomas J. Lynch, Jr. Oncologist 2001; 6: 407-414 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Know the currently acceptable chemotherapy regimens for first-line use in advanced non-small cell lung cancer along with their toxicity profiles. Understand the rationale behind the study of ISIS 3521 and OSI-744 in patients with non-small cell lung cancer. Appreciate the potential survival benefit of chemoradiotherapy for patients with stage IIIB non-small cell lung cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: July 10, 2002 Most Recent Review: June 10, 2005* Most Recent Update: July 10, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.